2
|
Toniolo C, Moretto A, Formaggio F, Broxterman QB, Crisma M. From Amherst (Massachusetts, USA) to Padua (Italy) and back again: Louis A. Carpino's scientifically productive journey. Pept Sci (Hoboken) 2020. [DOI: 10.1002/pep2.24153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Claudio Toniolo
- Department of ChemistryUniversity of Padua Via Marzolo 1, 35131 Padua Italy
- Institute of Biomolecular Chemistry, Padua UnitCNR Via Marzolo 1, 35131 Padua Italy
| | - Alessandro Moretto
- Department of ChemistryUniversity of Padua Via Marzolo 1, 35131 Padua Italy
- Institute of Biomolecular Chemistry, Padua UnitCNR Via Marzolo 1, 35131 Padua Italy
| | - Fernando Formaggio
- Department of ChemistryUniversity of Padua Via Marzolo 1, 35131 Padua Italy
- Institute of Biomolecular Chemistry, Padua UnitCNR Via Marzolo 1, 35131 Padua Italy
| | | | - Marco Crisma
- Institute of Biomolecular Chemistry, Padua UnitCNR Via Marzolo 1, 35131 Padua Italy
| |
Collapse
|
4
|
Littler BJ, Aizenberg M, Ambhaikar NB, Blythe TA, Curran TT, Dvornikovs V, Jung YC, Jurkauskas V, Lee EC, Looker AR, Luong H, Martinot TA, Miller DB, Neubert-Langille BJ, Otten PA, Rose PJ, Ruggiero PL. Development of a Manufacturing Process for an HCV Protease Inhibitor Candidate Molecule. Org Process Res Dev 2014. [DOI: 10.1021/op500210w] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Benjamin J. Littler
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Michael Aizenberg
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Narendra B. Ambhaikar
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Todd A. Blythe
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Timothy T. Curran
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Vadims Dvornikovs
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Young C. Jung
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Valdas Jurkauskas
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Elaine C. Lee
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Adam R. Looker
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Hoa Luong
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Theodore A. Martinot
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - David B. Miller
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Bobbianna J. Neubert-Langille
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Pieter A. Otten
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Peter J. Rose
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| | - Piero L. Ruggiero
- Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San
Diego, California 92121, United States
| |
Collapse
|
5
|
Ryan SJ, Francis CL, Savage GP. Benzonitrile Oxide Cycloadditions with Exocyclic Methylene Benzothiazepine Dioxides. Aust J Chem 2014. [DOI: 10.1071/ch13444] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
N-substituted 5-methylene-2,3,4,5-tetrahydrobenzo[f][1,2]thiazepine 1,1-dioxides underwent 1,3-dipolar cycloaddition with benzonitrile oxide, generated in situ, to give isoxazoline spiro adducts. The cycloadditions were completely regioselective to give the hitherto unreported 3,4-dihydro-2H,4′H-spiro[benzo[f][1,2]thiazepine-5,5′-isoxazole] 1,1-dioxide cycloadduct. Where the N-substituent on the sulfonamide cycloaddition precursor was a 2-substituted arene, the resulting atropisomerism along the N-aryl bond led to facial selectivity in the cycloaddition reaction, with greater than 90 % diastereoselectivity.
Collapse
|
7
|
Shih HW, Guo CW, Lo KH, Huang MY, Cheng WC. Solution-Phase Parallel Synthesis of Novel Spirooxazolinoisoxazolines. ACTA ACUST UNITED AC 2009; 11:281-7. [DOI: 10.1021/cc800158t] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Hao-Wei Shih
- The Genomics Research Center, Academia Sinica, No. 128, Academia Road Sec. 2, Nankang District, Taipei, 11529, Taiwan
| | - Chih-Wei Guo
- The Genomics Research Center, Academia Sinica, No. 128, Academia Road Sec. 2, Nankang District, Taipei, 11529, Taiwan
| | - Kien-Hock Lo
- The Genomics Research Center, Academia Sinica, No. 128, Academia Road Sec. 2, Nankang District, Taipei, 11529, Taiwan
| | - Min-Yang Huang
- The Genomics Research Center, Academia Sinica, No. 128, Academia Road Sec. 2, Nankang District, Taipei, 11529, Taiwan
| | - Wei-Chieh Cheng
- The Genomics Research Center, Academia Sinica, No. 128, Academia Road Sec. 2, Nankang District, Taipei, 11529, Taiwan
| |
Collapse
|
10
|
Conti P, Caligiuri A, Pinto A, Roda G, Tamborini L, Nielsen B, Madsen U, Frydenvang K, Colombo A, De Micheli C. Synthesis and pharmacological evaluation of novel conformationally constrained homologues of glutamic acid. Eur J Med Chem 2007; 42:1059-68. [PMID: 17346858 DOI: 10.1016/j.ejmech.2007.01.013] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2006] [Revised: 01/15/2007] [Accepted: 01/19/2007] [Indexed: 11/17/2022]
Abstract
Twelve novel conformationally constrained homologues of glutamic acid have been synthesized and pharmacologically characterized at ionotropic glutamate receptors (iGluRs). Synthesis of the target compounds involved 1,3-dipolar cycloaddition of nitrile oxides to suitable dipolarophiles. The structure to the compounds has been assigned by (1)H NMR and, in the case of derivatives (+/-)-4a, (+/-)-4b, (+/-)-5a, and (+/-)-5b, by means of an X-ray crystallographic analysis carried out on intermediate (+/-)-12a. The synthesized amino acids were found to be without affinity (K(i)/IC(50)>100microM) for iGluRs with the exception of compounds (+/-)-4b and (+/-)-5b, which showed a modest affinity for NMDA receptors (K(i)=34 and 13microM, respectively). The results indicate that the increased conformational constraints introduced by the cyclopropane ring and the spiro-attached proline ring are both detrimental to the pharmacological activity.
Collapse
Affiliation(s)
- Paola Conti
- Istituto di Chimica Farmaceutica e Tossicologica "Pietro Pratesi", Università degli Studi di Milano, Viale Abruzzi 42, 20131 Milano, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|